Utilization of Potassium Binders for the Management of Hyperkalemia in Chronic Kidney Disease: A Position Statement by US Nephrologists

Authors

Anjay Rastogi, Department of Medicine, David Geffen School of Medicine at UCLA Los Angeles, Los Angeles, CA.
Glenn M. Chertow, Department of Medicine, Stanford University School of Medicine, Stanford, CA.
Ashté Collins, Division of Renal Diseases and Hypertension, George Washington University School of Medicine, Washington, DC.
Ellie Kelepouris, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Wayne Kotzker, Florida Kidney Physicians, Boca Raton, FL.
John P. Middleton, Division of Nephrology, Department of Medicine, Duke University Medical Center, Durham, NC.
Minesh Rajpal, Southwest Kidney Institute, Phoenix, AZ.
Prabir Roy-Chaudhury, Division of Nephrology, Department of Medicine, University of North Carolina Kidney Center, Chapel Hill, NC and the WG (Bill) Hefner Salisbury VA Medical Center, Salisbury, NC. Electronic address: prabir_roy-chaudhury@med.unc.edu.

Document Type

Journal Article

Publication Date

11-1-2024

Journal

Advances in kidney disease and health

Volume

31

Issue

6

DOI

10.1053/j.akdh.2024.08.003

Keywords

Chronic kidney disease; Consensus; Hyperkalemia; Potassium binder; Sodium zirconium cyclosilicate

Abstract

Two potassium (K) binders-patiromer sorbitex calcium and sodium zirconium cyclosilicate-are recommended by international guidelines for the management of hyperkalemia. There is, however, no universally accepted best practice for how to appropriately utilize K binders in the long-term clinical management of CKD. A panel of eight US-based nephrologists convened in October 2022 to develop a consensus statement regarding utilizing K binders in clinical practice to help manage patients with nonemergent, persistent/recurrent hyperkalemia in CKD. Consensus was reached on the following topics: (1) identifying risk factors for hyperkalemia; (2) serum K monitoring before and during K binder use; (3) utilizing K binders in patients receiving renin-angiotensin-aldosterone system inhibitors and dialysis; and (4) when to initiate K binders and their duration of use. These consensus statements for the use of K binders may assist the nephrology community in optimizing management of hyperkalemia in patients across the spectrum of CKD.

APA Citation

Rastogi, Anjay; Chertow, Glenn M.; Collins, Ashté; Kelepouris, Ellie; Kotzker, Wayne; Middleton, John P.; Rajpal, Minesh; and Roy-Chaudhury, Prabir, "Utilization of Potassium Binders for the Management of Hyperkalemia in Chronic Kidney Disease: A Position Statement by US Nephrologists" (2024). GW Authored Works. Paper 6043.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/6043

Department

Medicine